Component

Blood glucose concentration

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Fasting blood glucose was not reduced by either nattokinase diet.

    Experimental context and source evidence
    duration
    14 days
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    experimental_model
    Rat (streptozotocin-induced diabetes)
    exposure
    Diet containing 0.2 or 0.6 mg nattokinase per gram
    limitations
    A measured null, and the reason the authors describe the renal and AGE effects as occurring without glycaemic correction. It agrees in sign with the small glucose rise in the human meta-analysis only in the sense that neither shows glucose falling.
    organism
    Rat (streptozotocin-induced diabetes)
    plain_language
    Fasting blood glucose was not reduced by either nattokinase diet.
    primary_references
    Effect of nattokinase on the pathological conditions in streptozotocin induced diabetic rats. (2024) https://pubmed.ncbi.nlm.nih.gov/38586318/ DOI: 10.1016/j.heliyon.2024.e28835
    route
    In vivo, oral
    tissue
    Fasting blood glucose

    Nattokinase: what the purified enzyme cleaves, what survives being eaten, and the gap between the two (2026-09-23) · lines 1335–1335

    Original AI-assisted curation built from a supplied entity-first document of 105 entities and 129 claims. Every reference in that document was resolved against live PubMed with its abstract read and its DOI cross-checked on 2026-09-23, and the EFSA novel-food opinion was retrieved and read in full. That check corrected two PMIDs that pointed at unrelated papers, two DOIs, and two papers recorded as carrying no erratum that do carry one; it also reversed three findings the supplied document had stated backwards. Two papers carry a published correction, recorded as such and not as a retraction. Three sources are not indexed in PubMed and are cited by what they have. Laboratory lineages are recorded, so the four papers from one group, the three from another and the two readings of a single applicant dossier cannot be counted as separate lines of support. Study-specific doses, units, populations and limitations retained; activity units are never converted between systems. Not publisher full text. · supports · Rat (streptozotocin-induced diabetes) · source_derived_draft · unverified_draft

    Fasting blood glucose was not reduced by either nattokinase diet.
    Complete structured claim and evidence
  2. Pooled blood glucose rose by 0.40 against placebo across the same randomized trials.

    Experimental context and source evidence
    duration
    Trial durations differ
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    experimental_model
    Human, meta-analysis of randomized controlled trials
    exposure
    Nattokinase supplementation
    limitations
    Small and of unstated clinical meaning, but signed and significant in the pooled analysis. It is absent from every narrative summary of nattokinase read during this curation.
    organism
    Human, meta-analysis of randomized controlled trials
    plain_language
    Pooled blood glucose rose by 0.40 against placebo across the same randomized trials.
    primary_references
    Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (2023) https://pubmed.ncbi.nlm.nih.gov/39076715/ DOI: 10.31083/j.rcm2408234
    route
    In vivo, oral
    tissue
    Blood glucose

    Nattokinase: what the purified enzyme cleaves, what survives being eaten, and the gap between the two (2026-09-23) · lines 1093–1093

    Original AI-assisted curation built from a supplied entity-first document of 105 entities and 129 claims. Every reference in that document was resolved against live PubMed with its abstract read and its DOI cross-checked on 2026-09-23, and the EFSA novel-food opinion was retrieved and read in full. That check corrected two PMIDs that pointed at unrelated papers, two DOIs, and two papers recorded as carrying no erratum that do carry one; it also reversed three findings the supplied document had stated backwards. Two papers carry a published correction, recorded as such and not as a retraction. Three sources are not indexed in PubMed and are cited by what they have. Laboratory lineages are recorded, so the four papers from one group, the three from another and the two readings of a single applicant dossier cannot be counted as separate lines of support. Study-specific doses, units, populations and limitations retained; activity units are never converted between systems. Not publisher full text. · supports · Human, meta-analysis of randomized controlled trials · source_derived_draft · unverified_draft

    Pooled blood glucose rose by 0.40 against placebo across the same randomized trials.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards